Investigational biologic, likely a monoclonal antibody; the specific target and mechanism are not specified in the trial record.
Enoblituzumab (TJ271) is a humanized, Fc-optimized IgG1 monoclonal antibody targeting B7-H3 (CD276) on tumor cells and tumor vasculature. By blocking B7-H3-mediated inhibitory signaling and engaging Fc gamma receptor-expressing effector cells, it induces antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis to kill tumor cells.
IgG1 antibody binds B7-H3 on tumor cells and engages FcγR-expressing effector cells (e.g., NK cells, macrophages) to induce ADCC and antibody-dependent cellular phagocytosis, killing target-expressing cells.
Lentiviral CAR T cells specific for CLL-1 (CLEC12A); IV infusion with dose escalation; intended to eliminate CLL-1+ myeloid leukemia stem cells and myeloid blasts via MHC-independent mechanisms.
Genetically engineered T cells (via lentiviral transduction) expressing a CAR that recognizes CLL‑1/CLEC12A on myeloid leukemia stem cells and blasts. Antigen binding activates T cells independent of MHC, inducing cytotoxicity (perforin/granzyme) and cytokine release to eliminate CLL‑1–positive malignant cells.
CLL-1 (CLEC12A)-targeted CAR T cells bind CLEC12A on target cells and induce MHC-independent T-cell cytolysis via perforin/granzyme (and apoptotic pathways).
Chimeric anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, reducing auto/alloantibody production and germinal center activity.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, reducing auto/alloantibody production and germinal center activity.
Rituximab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated effector killing (ADCC/ADCP), with possible direct apoptosis, depleting CD20+ cells.
Oral small-molecule BCL-2 inhibitor (BH3 mimetic) that restores mitochondrial apoptosis in BCL-2–dependent CLL cells.
Selective oral BCL-2 inhibitor (BH3 mimetic) that binds the hydrophobic groove of BCL-2, neutralizes its anti-apoptotic function, and restores mitochondrial apoptosis in BCL-2–dependent tumor cells; spares BCL-XL, reducing thrombocytopenia risk.
Venetoclax directly inhibits BCL-2, freeing pro-apoptotic BH3-only proteins to activate BAX/BAK, inducing mitochondrial outer membrane permeabilization, caspase activation, and apoptosis in BCL‑2–dependent cells.
Intravenous chimeric monoclonal antibody against CD20 that depletes B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct apoptosis.
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on B cells and depletes them via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and induction of apoptosis.
Rituximab binds CD20 on B cells and depletes them via Fc-mediated ADCC by NK cells/macrophages, complement-dependent cytotoxicity (CDC), and induction of apoptosis.